European CHMP supports licence change for ataluren (Translarna) for non-ambulatory patients with Duchenne muscular dystrophy

The Committee supports the removal of the statement "efficacy has not been demonstrated in non-ambulatory patients" from SmPC thus enabling healthcare professionals to use their clinical judgement to make treatment decisions for their patients on ataluren who have lost ambulation


Biospace Inc.